Author/Editor		Poredoš, Pavel
Title		Klopidogrel - nova možnost preprečevanja srčno-žilnih zapletov
Translated title		Clopidogrel - a new opportunity for preventing cardiovascular complications
Type		članek
Source		Med Razgl
Vol. and No.		Letnik 40, št. Suppl 1
Publication year		2001
Volume		str. 141-5
Language		slo
Abstract		This paper describes an antithrombotic drug, clopidogrel, which inhibits platelet activation through ADP receptors. Clopidogrel significantly reduces the incidence of thromboembolic complications inpatients with atherosclerotic disease. Its efficacy has been proven in numerous preclinical and clinical studies. The most relevant results concerning its efficacy were obtained in CAPRIE study. This study showed that clopidogrel prevents complications in patients with myocardial infarction, stroke and peripheral arterial occlusive disease as efficiently as aspirin, or even better. Data obtained to date indicate that clopidogrel is a relatively safe drug. Digestive problems are as frequent as with other antiplatelet drugs, while gastrointestinal bleeding and disturbances of blood clotting are even less frequent than with aspirin. Serious complications (neutropenia, thrombotic thrombocytopenic purpura), which are associated with ticlopidine, a precursor of clopidogrel; are less frequent with clopidogrel treatment. Clopidogrel can be considered a significant advance in the field of secondary prevention of atherosclerosis. Its use is indicated predominantly in patients with generalized atherosclerosis in whom aspirin is contraindicated.
Summary		V prispevku je opisano novejše protitrombocitno zdravilo - klopidogrel, ki zavira aktivacijo trombocitov preko ADP receptorjev. Klopidogrel pomembno zmanjša pogostost trombemboličnih zapletov pri bolnikih z že prisotno aterosklerotično boleznijo. Učinkovitost zdravila je bila dokazana v številnih predkliničnih in kliničnih raziskavah. Najzaneslivejše podatke o učinkovitosti zdravila je dala raziskava CAPRIE. Ta raziskava je pokazala, da klopidogrel enako ali celo bolj učinkovito kot aspirin, preprečuje zaplete pri bolnikih z miokardnim infarktom, z možgansko kapjo in periferno arterijsko boleznijo. Dosedanje izkušnje so pokazale, da je klopidogrel razmeroma varno zdravilo. Prebavne težave se pojavljajo enako pogosto kot pri drugih protitrombocitnih zdravilih, krvavitve v prebavila in motnje strjevanja krvi pa so pri klopidogrelu redkejše kot pri aspirinu. Nevarni zapleti, ki spremljajo zdravljenje s tiklopidinom, kot predhodnikom klopidogrela (neutropenija, trombotična trombocitopenična purpura), se pri klopidogrelu pojavljajo redkeje. Klopidogrel pomeni pomembno novost na področju sekundarne preventive ateroskleroze, njegova uporaba je smiselna zlasti pri generalizirani aterosklerotični bolezni in v primerih, ko je uporaba aspirina kontraindicirana.
Descriptors		THROMBOEMBOLISM PLATELET AGGREGATION INHIBITORS